Telbivudine
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: beta-L-Thymidine, epavudine, L-Thymidine, sebivo
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Telbivudine is an ofm drug in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2006. Its mechanism of action is classified as Nucleoside Reverse Transcriptase Inhibitors. DrugCentral lists 2 molecular targets, including HBcAg and P. Recorded indications include Chronic type B viral hepatitis.
- Approval status: ofm (first approved 2006 by the FDA).
- Drug class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
- Mechanism of action: Nucleoside Reverse Transcriptase Inhibitors.
- Molecular targets: HBcAg and P (2 listed in DrugCentral).
- Indications: Chronic type B viral hepatitis.
- ATC code: J05AF11 (Nucleoside and nucleotide reverse transcriptase inhibitors).
- Molecular formula: C10H14N2O5; molecular weight 242.23 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Chronic type B viral hepatitis
Contraindications (7)
- Breastfeeding (mother)
- Disorder of muscle
- Kidney disease
- Lactic acidosis
- Myositis
- Peripheral nerve disease
- Steatosis of liver
Mechanism & targets
| Mechanism of action (MoA) | Nucleoside Reverse Transcriptase Inhibitors |
|---|---|
| Established pharmacologic class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Capsid protein | HBcAg | unknown | EC50 6.09 |
| Protein P | P | inhibitor | EC50 5.89 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2007-04-24 | EMA | — | — | |
| 2006-10-25 | FDA | — | NOVARTIS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AF11 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleoside and nucleotide reverse transcriptase inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug resistance | 394.3 |
| Blood creatine phosphokinase increased | 234.9 |
| Pathogen resistance | 205.8 |
| Viral mutation identified | 183.9 |
| Hepatitis B DNA increased | 125.7 |
| Myalgia | 97.1 |
Chemical structure
| Molecular formula | C10H14N2O5 |
|---|---|
| Molecular weight | 242.23 g/mol |
| CAS number | 3424-98-4 |
| InChIKey | IQFYYKKMVGJFEH-CSMHCCOUSA-N |
| PubChem CID | 159269 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Telbivudine used for?
DrugCentral lists the following indications for Telbivudine: Chronic type B viral hepatitis.
How does Telbivudine work?
Telbivudine is classified as Nucleoside Reverse Transcriptase Inhibitors; its molecular targets in DrugCentral include HBcAg and P (inhibitor).
When was Telbivudine first approved?
Telbivudine was first approved by the FDA in 2006.
What drug class does Telbivudine belong to?
Telbivudine is in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class.
What is the chemical formula of Telbivudine?
Telbivudine has the molecular formula C10H14N2O5 and a molecular weight of 242.23 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4220 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL374731 — compound record and bioactivity
- PubChem CID 159269 — chemical identifiers
- DrugBank DB01265 — drug record
- FDA UNII 2OC4HKD3SF — substance identity
- DailyMed: FDA labels for Telbivudine — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.